Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Atidarymo kaina

2.45 -0.41

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.43

Max

2.54

Pagrindiniai rodikliai
By Trading Economics
Pajamos	663K -7M
Pardavimai	426K 2.6M
P/E Sektoriaus vid.	6.816 56.597
Pelnas, tenkantis vienai akcijai	-0.07
Pelno marža	-269.254
Darbuotojai	75
EBITDA	665K -7M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+101.61% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	20M 245M
Ankstesnė atidarymo kaina	2.86
Ankstesnė uždarymo kaina	2.45

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-09 23:56; UTC

Revolve Group Inc shares are higher in after-market hours, maintaining an upward trend since Wednesday's close, despite being below the 20-day moving average.

2026-09-09 23:56; UTC

Correlated Moves

Procore Technologies Inc shares are higher in after-market hours, recovering from an initial decline. The stock remains below its 20-day moving average.

2026-09-09 23:56; UTC

BlackLine Inc. shares rose in after-market trading, recovering from an initial dip. The stock remains below its 20-day moving average amid broader market challenges.

2026-09-09 23:56; UTC

MetLife Inc shares are lower in after-market hours amid heightened market anxiety over geopolitical tensions and upcoming economic data releases.

2026-09-09 23:56; UTC

Warner Bros Discovery Inc. shares are higher in after-market trading, despite earlier fluctuations and amid broader market anxiety over geopolitical tensions and economic data.

2026-09-09 23:56; UTC

JinkoSolar Holding Co Ltd shares are lower in after-market hours, continuing a decline amid market anxiety over geopolitical tensions and upcoming economic data releases.

2026-09-09 23:56; UTC

No specific news was identified for Solaredge Technologies. Shares traded roughly flat in after-market hours, remaining near the upper end of their one-month range.

2026-09-09 23:53; UTC

Gossamer Bio Inc. shares are lower in after-market hours following a significant decline since Wednesday's close, despite an earlier attempt to recover.

2026-09-09 23:52; UTC

ACI Worldwide shares declined in after-market trading, continuing a downward trend from regular trading and reflecting ongoing selling pressure amid broader market conditions.

2026-09-09 23:52; UTC

The NZD/CHF is trading lower during Wednesday's session, reflecting routine movement near its one-month trading range's lower end. No specific news was identified.

2026-09-09 23:51; UTC

Correlated Moves

Ares Management shares are higher in after-market trading, reflecting positive market conditions and aligning with upward trends in correlated assets like Brookfield Corp.

2026-09-09 23:51; UTC

Correlated Moves

ACNB Corp shares are lower in after-market hours, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

2026-09-09 23:51; UTC

News

Toll Brothers Inc. shares are lower in after-market trading, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

2026-09-09 23:51; UTC

Lamb Weston Holdings Inc shares are higher in after-market hours, reflecting an increase since Wednesday's close, despite recent underperformance and no specific news identified.

2026-09-09 23:51; UTC

ManpowerGroup Inc. shares are lower in after-market hours, continuing a decline below the 20-day moving average amid broader market weakness.

2026-09-09 23:51; UTC

MVB Financial Corp shares traded higher in after-market hours, reaching 0.42% above Wednesday's close and remaining above their 20-day moving average.

2026-09-09 23:51; UTC

Travelers Companies Inc shares are higher in after-market hours, reaching a peak return after an initial dip. No specific news was identified for this movement.

2026-09-09 23:51; UTC

Movado Group Inc shares are lower in after-market hours, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

2026-09-09 23:51; UTC

UK Housing Market Shows Signs of Stabilization with Slight Improvement in House Price Balance, Amidst Cautious Optimism and Ongoing Economic Challenges

2026-09-09 23:51; UTC

Existing Home Sales Expected to Decline Amid High Mortgage Rates and Decreased Buyer Demand

2026-09-09 23:51; UTC

US Existing Home Sales Data for August 2026 Expected at 3.98 Million Amid Rising Inventory and High Mortgage Rates.

2026-09-09 23:51; UTC

Brazil's Central Bank Faces Critical Interest Rate Decision Amid Inflation Concerns and Economic Resilience on September 16, 2026.

2026-09-09 23:51; UTC

Chubb Limited shares are lower in after-market hours, continuing a trend of declining prices. The stock is below its 20-day moving average.

2026-09-09 23:51; UTC

Amerisafe Inc shares are higher after market hours, despite a slight decline earlier. The stock remains below its 20-day moving average.

2026-09-09 23:51; UTC

Correlated Moves

Carlyle Group Inc is trading higher in after-market hours, rebounding from three consecutive lower sessions amid broader positive market dynamics despite rising crude oil prices.

2026-09-09 23:51; UTC

Patrick Industries Inc. shares declined after market hours, continuing a trend of lower closes. The stock remains significantly below the 20-day moving average.

2026-09-09 23:51; UTC

News

Lakeland Industries reported a fiscal Q2 net loss of $4.9 million and lower-than-expected sales, leading shares to decline in after-market trading.

2026-09-09 23:51; UTC

News

Limoneira Co reported third-quarter results that missed expectations, with revenues falling to $43.8 million and shares trading lower in after-market hours.

2026-09-09 23:51; UTC

Correlated Moves

EUR/CHF is trading higher, recovering from earlier lows and reflecting unusual intraday activity near the upper end of its one-month range.

2026-09-09 23:51; UTC

GBP/CHF is trading higher during Wednesday's session, recovering from an early dip and settling near the upper end of its one-month trading range.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

101.61% į viršų

12 mėnesių prognozė

Vidutinis 5 USD 101.61%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.